Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)
ConclusionsThese findings indicate that S-1 plus docetaxel as first-line treatment for older patients is feasible and that it has promising efficacy against advanced gastric cancer.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Study | Taxotere | Toxicology